Pembrolizumab Vs Chemotherapy in the First-Line Setting of PD-L1≥50% Metastatic Non-Small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis.
JCO Oncology Practice（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined